Revolutionizing Cervical Cancer Prevention: New Guidelines and Diagnostic Test Offer Personalized Care
CLARKSBURG, MARYLAND / ACCESS Newswire / January 29, 2025 / Clinicians and patients working to prevent cervical cancer now have new personalized options thanks to guidance published this month. Human papillomaviruses (HPVs) cause most cervical cancers, but different HPV types carry different risks. A new test from BD Diagnostic Systems (Onclarity HPV assay) informs clinicians about not just HPV infections but responsible HPV types. New guidelines from a national panel led by ASCCP and the National Cancer Institute provide guidance on management and were published in the Journal of Lower Genital Tract Disease.
'Under the new guidelines, women and people with cervices with more aggressive types can be referred expeditiously to magnified cervical assessment with colposcopy. Those with the least risky types can be observed for a year. Intermediate-risk types should be triaged with a Pap test or the related CINtec Plus assay from Roche Diagnostics - those with normal results should be observed, while those with abnormal results are referred to colposcopy. The new assay can also be used with the traditional Pap test for individualized management.'
The manuscript may be found here: Extended Genotyping.
The American Society for Colposcopy and Cervical Pathology (ASCCP) is dedicated to improving the health of women through the delivery of high-quality, evidence-based care. ASCCP is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
15 hours ago
- Yahoo
What's Behind Hologic's Positive Long-Term Outlook for Cytology Unit?
Hologic HOLX is a leading name in the cytology space, with its Cytology business, part of its Diagnostics franchise, primarily focusing on screening for cervical cancer. The company has pioneered the first FDA-approved liquid-based cytology test — the ThinPrep Pap test — and the first FDA-approved mRNA-based HPV test — the Aptima HPV Assay. Co-testing — combining a Pap test with an HPV test — is the most sensitive testing option for cervical cancer screening compared to either test used alone. While this business of Hologic has historically been a flattish to single-digit grower, the company has continued to invest in it, like the 2024 launch of the Genius digital cytology system. It was a significant introduction, marking the only FDA-cleared digital cytology system that combines deep-learning-based AI with advanced volumetric imaging technology to help identify pre-cancerous lesions and cervical cancer cells. HOLX management noted that if not for the sales headwinds in China, Cytology would have grown in low single digits in the second quarter of fiscal 2025, driven by the rollout of its Genius digital diagnostics system, instead of reporting a 2.2% decline. With more labs around the world implementing this in-house innovation, Hologic has received strong positive feedback. Genius replaces the traditional manual review of path slides, which was previously conducted on glass under a microscope, by capturing a digital image of the slide, which can be reviewed remotely from anywhere in the customer's network on the company's review station. These workflow advantages not only address their growing labor shortages but also enable cervical cancer screening in regions with limited infrastructure. Because the Genius system requires an overhaul of the traditional pet screening workflow, Hologic expects the full rollout to be a multi-year process, serving as a growth driver for the next several quarters. HOLX's Peers in Cervical Cancer Screening Quest Diagnostics DGX offers a complete menu of solutions for screening and diagnosing cervical cancer. In April this year, DGX introduced a new solution aimed at expanding access to human papillomavirus (HPV) screening to help identify women who are at risk of developing cervical cancer. With this new offering, physicians can offer patients the option to collect their specimen for HPV screening in a physician's office or other healthcare setting. Quest Diagnostics' latest test uses the FDA-cleared HPV self-collection solution from Roche, approved for use with Roche Holding AG's RHHBY cobas HPV test in May 2024. Roche's cervical cancer portfolio includes three clinically validated tests to help identify women at risk and improve the detection of high-grade disease in a single round of screening. The cobas HPV test is the first clinically validated, FDA-approved, CE-IVD marked HPV DNA test for all cervical screening indications — primary screening, ASC-US triage and co-testing. The CINtec PLUS Cytology test is the only FDA-approved triage test that uses dual biomarker technology to simultaneously detect p16 and Ki-67 in women with HPV-positive results. Roche's CINtec Histology test uses advanced p16 biomarker technology to confirm cervical lesions due to transforming HPV infections. HOLX Stock Performance, Valuation and Estimates In the past six months, Hologic shares have risen 5.2% against the industry's 11.9% fall. Image Source: Zacks Investment Research Hologic is trading at a forward three-year price-to-earnings of 15.23X, lower than the industry average of 28.67X. The stock carries a Value Score of B at present. Image Source: Zacks Investment Research Consensus estimates for Hologic's fiscal 2025 earnings are showing a mixed trend. Image Source: Zacks Investment Research HOLX stock currently carries a Zacks Rank #3 (Hold).You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Roche Holding AG (RHHBY) : Free Stock Analysis Report Quest Diagnostics Incorporated (DGX) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Los Angeles Times
a day ago
- Los Angeles Times
U.S. pediatricians' new COVID-19 vaccine recommendations differ from CDC advice
NEW YORK — For the first time in 30 years, the American Academy of Pediatrics is substantially diverging from U.S. government vaccine recommendations. The group's new COVID-19 recommendations — released Tuesday — come amid a tumultuous year for public health, as vaccine skeptics have come into power in the new Trump administration and government guidance has become increasingly confusing. This isn't going to help, acknowledged Dr. James Campbell, vice chair of the AAP infectious diseases committee. 'It is going to be somewhat confusing. But our opinion is we need to make the right choices for children to protect them,' he added. The AAP is strongly recommending COVID-19 shots for children ages 6 months to 2 years. Shots also are advised for older children if parents want their kids vaccinated, the AAP said. That differs from guidance established under U.S. Health Secretary Robert F. Kennedy Jr., which doesn't recommend the shots for healthy children of any age but says kids may get the shots in consultation with physicians. Children ages 6 months to 2 years are at high risk for severe illness from COVID-19, and it was important that recommendations continue to emphasize the need for them to get vaccinated, said Campbell, a University of Maryland infectious diseases expert. Vaccinations also are recommended for older children who have chronic lung diseases or other conditions that put them at higher risk for severe disease, the AAP said. In a statement, Department of Health and Human Services spokesperson Andrew Nixon said 'the AAP is undermining national immunization policymaking with baseless political attacks.' He accused the group of putting commercial interests ahead of public health, noting that vaccine manufacturers have been donors to the AAP's Friends of Children Fund. The fund is currently paying for projects on a range of topics, including health equity and prevention of injuries and deaths from firearms. The 95-year-old Itasca, Illinois-based organization has issued vaccination recommendations for children since the 1930s. In 1995, it synced its advice with recommendations made by the federal government's Centers for Disease Control and Prevention. There have been a few small differences between AAP and CDC recommendations since then. For example, the AAP has advised that children get HPV vaccinations starting at age 9; the CDC says that's OK but has emphasized vaccinations at ages 11 and 12. But in 30 years, this is the first time the recommendations have differed 'in a significant or substantial way,' Campbell said. Until recently, the CDC — following recommendations by infectious disease experts — has been urging annual COVID-19 boosters for all Americans ages 6 months and older. But in May, U.S. Health Secretary Robert F. Kennedy Jr. announced that COVID-19 vaccines are no longer recommended for healthy children and pregnant women. A few days later, the CDC issued language that healthy children may get the shots, but that there was no longer a 'should' recommendation. The idea that healthy older kids may be able to skip COVID-19 boosters has been brewing for some time among public health experts. As the COVID-19 pandemic has waned, experts have increasingly discussed the possibility of focusing vaccination efforts on people 65 and older — who are among those most as risk for death and hospitalization. A CDC expert panel in June was set to make recommendations about the fall shots. Among the options the panel was considering was whether suggest shots for high-risk groups but still giving lower-risk people the choice to get vaccinated. But Kennedy bypassed the group, and also decided to dismiss the 17-member panel and appoint his own, smaller panel, that included vaccine skeptics. Kennedy also later excluded the AAP, the American Medical Association and other top medical organizations from working with the advisers to establish vaccination recommendations. Kennedy's new vaccine panel has yet to vote on COVID-19 shot recommendations. The panel did endorse continuing to recommend fall flu vaccinations, but also made a decision that led to another notable difference with the AAP. The new advisory panel voted that people should only get flu vaccines that are packaged as single doses and do not contain the preservative thimerosal. The AAP said there is no evidence of harm from the preservative, and recommended doctors use any licensed flu vaccine product that's appropriate for the patient. Stobbe writes for the Associated Press. The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Yahoo
a day ago
- Yahoo
US pediatricians contradict US government for first time in 30 years over Covid vaccine advice for babies
For the first time in three decades, the American Academy of Paediatrics has significantly diverged from official US government vaccine recommendations, issuing new guidance on Covid-19 shots for children. The move comes amid a tumultuous year for public health, as vaccine sceptics have gained influence within the current US administration and government guidance has become increasingly confusing. "It is going to be somewhat confusing. But our opinion is we need to make the right choices for children to protect them," acknowledged Dr James Campbell, vice chair of the AAP infectious disease committee. The AAP is now strongly recommending Covid-19 vaccinations for children aged six months to two years. Shots are also advised for older children if their parents wish for them to be vaccinated, the organization stated. This contrasts sharply with guidance established under US Health Secretary Robert F. Kennedy Jr., which does not recommend the shots for healthy children of any age, instead suggesting they may receive them in consultation with physicians. Dr Campbell, an infectious diseases expert at the University of Maryland, emphasized that children aged six months to two years are at high risk for severe illness from Covid-19, making continued vaccination recommendations crucial for this age group. Vaccinations are also recommended by the AAP for older children with chronic lung diseases or other conditions that elevate their risk for severe disease. The 95-year-old Itasca, Illinois-based organisation has been issuing vaccination recommendations for children since the 1930s. In 1995, it aligned its advice with recommendations from the federal government's CDC. While there have been minor differences since then – for instance, the AAP advising HPV vaccinations from age nine, while the CDC emphasized ages 11 and 12 – this marks the first time in 30 years that the recommendations have differed "in a significant or substantial way," according to Dr Campbell. Until recently, the CDC, following expert advice, had been urging annual Covid-19 boosters for all Americans aged six months and older. However, in May, US Health Secretary Robert F. Kennedy Jr. announced that Covid-19 vaccines were no longer recommended for healthy children and pregnant women. Days later, the CDC adjusted its language, stating that healthy children may get the shots, but removing the previous "should" recommendation. The notion that healthy older children might skip Covid-19 boosters has been discussed among public health experts as the pandemic has waned, with increasing focus on vaccinating those aged 65 and older, who face the highest risk of death and hospitalization. A CDC expert panel was set to make recommendations for autumn shots in June, considering options such as suggesting shots for high-risk groups while allowing lower-risk individuals the choice. However, Mr Kennedy bypassed this group, dismissing the 17-member panel and appointing his own, smaller panel, which included vaccine sceptics. He subsequently excluded the AAP, the American Medical Association, and other leading medical organizations from collaborating with these new advisers on vaccination recommendations. Mr Kennedy's new vaccine panel has yet to vote on Covid-19 shot recommendations. The panel did endorse continuing to recommend autumn flu vaccinations, but also made a decision that led to another notable difference with the AAP. The new advisory panel voted that individuals should only receive flu vaccines packaged as single doses and free of the preservative thimerosal. The AAP, however, stated there is no evidence of harm from the preservative and recommended that doctors use any licensed flu vaccine product appropriate for the patient. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
